What are the current guidelines for assessing risk and managing tumor lysis syndrome?

Management of Tumor Lysis Syndrome: Current Guidelines

Risk Stratification

All patients must undergo pre-treatment risk assessment before initiating cytotoxic therapy to determine prophylaxis intensity. 1

High-Risk Criteria

• Host factors: Pre-existing renal impairment (including malignant infiltration), dehydration, obstructive uropathy, hyperuricemia >8 mg/dL in children or >10 mg/dL in adults 2, 1
• Disease factors: Bulky disease, high-grade lymphomas (especially Burkitt lymphoma), acute lymphoblastic leukemia (adult ALL or advanced pediatric T-cell ALL), white blood cell count >100 × 10⁹/L, LDH >2× upper normal limit 2, 1
• Therapy factors: Intensive polychemotherapy including cisplatin, cytarabine, etoposide, methotrexate 2

Pre-Treatment Evaluation

• Obtain creatinine clearance (or estimated GFR), serum LDH, baseline electrolytes (potassium, phosphorus, calcium), and uric acid in all patients 2, 1
• Perform renal ultrasound in all patients scheduled for chemotherapy 2, 1
• Patients with prior TLS episodes require nephrology consultation before restarting therapy 2, 1

---

Prophylaxis by Risk Level

High-Risk Patients

High-risk patients require aggressive intravenous hydration combined with rasburicase—not allopurinol—as the primary prophylactic agent, delivered in an inpatient setting with immediate dialysis access. 1

Rasburicase Regimen

• Dose: 0.20 mg/kg/day IV over 30 minutes for 3–5 days 2, 1
• Timing: First dose administered ≥4 hours before chemotherapy initiation 2, 1
• Superiority over allopurinol: Rasburicase achieves 86% reduction in plasma uric acid within 4 hours versus only 12% with allopurinol (p<0.0001) 1
• Mean uric acid area-under-curve: 128±70 mg·dL⁻¹·h with rasburicase versus 329±129 mg·dL⁻¹·h with allopurinol (p<0.001) 1
• Dialysis required in only 2.6% of rasburicase patients versus 16% with allopurinol 1

Mandatory Screening Before Rasburicase

• Screen for G6PD deficiency in all patients, especially those of African or Mediterranean ancestry—rasburicase is absolutely contraindicated in G6PD deficiency due to risk of severe hemolysis and methemoglobinemia 1
• Contraindications also include history of anaphylaxis to rasburicase, pregnancy, and lactation 1

Hydration Protocol

• Initiate aggressive IV hydration ≥48 hours before chemotherapy when possible 2, 1
• Target urine output: ≥100 mL/hour in adults (3 mL/kg/hour in children <10 kg) 2, 1
• Deliver 2–3 L/m²/day of IV fluids 1
• Initial fluids should exclude potassium, calcium, and phosphate 1
• Add loop diuretics (not thiazides) if target urine output cannot be achieved, except in obstructive uropathy or hypovolemia 2, 1

Critical Drug Interaction

• Never administer allopurinol concurrently with rasburicase—this causes xanthine accumulation and risk of xanthine crystal deposition in renal tubules 2, 1
• After completing rasburicase (3–5 days), transition to oral allopurinol 2, 1

Intermediate-Risk Patients

• Aggressive hydration (≥2 L/m²/day) plus either allopurinol 300 mg daily or rasburicase 0.2 mg/kg/day 1
• Agent selection based on baseline uric acid level and renal function 1

Low-Risk Patients

• Vigorous hydration (≥2 L/m²/day) plus oral allopurinol 100 mg/m² three times daily (maximum 800 mg/day) 2, 1
• Start allopurinol 1–2 days before chemotherapy and continue for 3–7 days 1
• In renal impairment, reduce allopurinol dose by ≥50% because both drug and metabolite (oxipurinol) accumulate renally 1, 3

---

Monitoring Protocols

High-Risk Patients (Before TLS Develops)

• Monitor LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, and calcium every 12 hours for first 3 days, then every 24 hours 2, 1

Patients with Established TLS

• First 24 hours: Monitor vital signs, serum uric acid, electrolytes (potassium, phosphate, calcium), and renal function every 6 hours 2, 1
• Days 2–3: Continue monitoring every 12 hours 1
• Subsequently: Daily monitoring until stable 2, 1
• Blood cell count, serum LDH, albumin, blood gases, ECG, and body weight every 24 hours 2

Critical Sample Handling

• Place blood samples immediately on ice to prevent ex vivo enzymatic degradation by rasburicase, which falsely lowers measured uric acid 1

---

Management of Metabolic Abnormalities

Hyperkalemia (≥6 mmol/L)

Severe hyperkalemia requires immediate multi-modal therapy with continuous ECG monitoring. 1

• Rapid insulin 0.1 U/kg IV plus 25% dextrose 2 mL/kg IV 1
• Calcium gluconate 50–100 mg/kg IV to stabilize cardiac membranes 1
• Sodium bicarbonate to correct metabolic acidosis 1
• Sodium polystyrene sulfonate ≈1 g/kg orally or via enema 1
• Continuous ECG monitoring is mandatory 1
• Loop diuretics are contraindicated in anuric or oliguric patients despite adequate hydration 1

Hyperphosphatemia

• Mild (<1.62 mmol/L): Aluminum hydroxide 50–100 mg/kg/day divided in 4 doses (oral or nasogastric) 1
• Severe hyperphosphatemia with symptomatic hypocalcemia is an indication for dialysis 1

Hypocalcemia

Asymptomatic hypocalcemia should NOT be treated when hyperphosphatemia is present—calcium administration can precipitate metastatic calcifications and worsen renal function. 1

• Only treat if symptomatic (tetany, seizures, prolonged QT): Calcium gluconate 50–100 mg/kg as single IV dose, cautiously repeated if necessary 1

Hyperuricemia

• If uric acid remains >7.5 mg/dL or is rising: Rasburicase is preferred over allopurinol because allopurinol only prevents new uric acid formation and cannot lower existing hyperuricemia 1
• Rasburicase converts existing uric acid to allantoin, which is 5–10 times more soluble 1

---

Important Considerations

Urine Alkalinization

• Urine alkalinization is NOT recommended, especially when rasburicase is used, because it increases risk of calcium-phosphate precipitation 2, 1

Drug Interactions

• When allopurinol is combined with 6-mercaptopurine or azathioprine, reduce thiopurine dose by 65–75% to avoid toxicity 1, 3

Rasburicase Advantages

• Allows earlier administration of chemotherapy due to rapid uric acid degradation 2, 1
• Time to uric acid control: 4 hours with rasburicase versus 27 hours with allopurinol alone 1

---

Indications for Renal Replacement Therapy

Dialysis should be initiated for: 1

• Severe oliguria or anuria unresponsive to medical management
• Persistent hyperkalemia despite medical therapy
• Hyperphosphatemia with symptomatic hypocalcemia
• Hyperuricemia not responding to rasburicase
• Severe volume overload
• Symptomatic uremia (refractory nausea, vomiting, encephalopathy)

Hemodialysis reduces plasma uric acid by approximately 50% with each 6-hour treatment 1

---

Resuming Chemotherapy After TLS

Pre-Resumption Requirements

Nephrology consultation is mandatory before restarting therapy in any patient with previous clinical TLS. 4

Laboratory Thresholds

• Uric acid <475 μmol/L (8 mg/dL) 4
• Creatinine <141 μmol/L 4
• pH ≥7.0 4
• All electrolytes (potassium, phosphate, calcium) normalized 4

Prophylaxis for Subsequent Cycles

• All patients with prior TLS require rasburicase prophylaxis (0.20 mg/kg/day for 3–5 days) for every subsequent chemotherapy cycle 4
• Initiate aggressive IV hydration 48 hours before chemotherapy resumption, targeting urine output ≥100 mL/hour 4
• Loop diuretics may be required to maintain target urine output 4

Post-Resumption Monitoring

• First 24 hours: Monitor every 6 hours 4
• Days 2–3: Monitor every 12 hours 4
• Continue daily monitoring until stable 4

Critical Pitfalls to Avoid

• Premature resumption before metabolic abnormalities are corrected leads to recurrent TLS 4
• Inadequate hydration when restarting chemotherapy increases risk of recurrent renal injury 4
• Omission of rasburicase prophylaxis substantially raises likelihood of recurrent TLS 4

---

Key Updates from Recent Evidence

• The 2023 modified Delphi panel emphasizes that hydration is the cornerstone of both TLS prophylaxis and management, with equal attention required for dangerous electrolyte abnormalities beyond uric acid, particularly hyperkalemia and hyperphosphatemia 5
• Contemporary guidelines now account for potent novel oncologic agents and immune checkpoint inhibitors that increase TLS risk 5, 6
• Serum phosphate concentration is emerging as the most important risk factor associated with clinical TLS in the rasburicase era 7